证券记录 · 已归档季度
URGN
UroGen Pharma Ltd. · Healthcare · Biotechnology
12被追踪持有人
—Δ持有人
7.91M持有股份
$132.72M报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 76 | +11 | 16.33M | $599.97M | +14 | −3 |
| Q1 2026 | 68 | -2 | 16.64M | $299.41M | +7 | −9 |
| Q4 2025 | 71 | 0 | 16.74M | $392.08M | — | — |
| Q3 2025 | 18 | -2 | 12.72M | $253.85M | — | −2 |
| Q2 2025 | 17 | +1 | 7.27M | $99.60M | +1 | — |
| Q1 2025 | 13 | 0 | 4.33M | $47.90M | — | — |
| Q4 2024 | 13 | +2 | 6.43M | $68.46M | +2 | — |
| Q3 2024 | 10 | -2 | 7.92M | $100.53M | — | −2 |
| Q2 2024 | 12 | — | 7.91M | $132.72M | — | — |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 3.30M | — | $55.37M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Point72 Asset Management ✦ | 2.45M | — | $41.10M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 1.16M | — | $19.48M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (被动) | 421.39K | — | $7.07M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (被动) | 421.39K | — | $7.07M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 156.08K | — | $2.62M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 156.08K | — | $2.62M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 156.08K | — | $2.62M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 156.08K | — | $2.62M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | ARK Investment Management ✦ | 151.78K | — | $2.55M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 100.42K | — | $1.69M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 74.36K | — | $1.25M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 74.36K | — | $1.25M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 42.84K | — | $718,872 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 42.84K | — | $718,872 | 0.0% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 30.29K | — | $508,266 | 0.0% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 30.29K | — | $508,266 | 0.0% | n/c | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 30.29K | — | $508,266 | 0.0% | n/c | 1 | SEC ↗ |
| 19 | T. Rowe Price ✦ | 10.95K | — | $184,000 | 0.0% | n/c | 1 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 10.84K | — | $181,946 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 171 持有人, 46.40M 股份, $801.72M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据